Stanford Hospital & Clinics in Palo Alto, Calif., announced the opening of its new clinical neurogenetics oncology program.
The program is designed to treat complex tumor-multiplying diseases, such as neurofibromatosis 2, schwannomatosis tuberous sclerosis, von Hippel-Lindau disease, Sturge Weber syndrome and hemorrhagic telangiectasia. These disorders are rare and often have no cure.
The program includes a multidisciplinary team that provides ongoing surveillance and coordination of all treatments and check-ups.
Pacific Cancer Institute of Maui to Begin $7M Expansion
Mayo Clinic Names Coborn Cancer Center First Member of New Cancer Care Network
The program is designed to treat complex tumor-multiplying diseases, such as neurofibromatosis 2, schwannomatosis tuberous sclerosis, von Hippel-Lindau disease, Sturge Weber syndrome and hemorrhagic telangiectasia. These disorders are rare and often have no cure.
The program includes a multidisciplinary team that provides ongoing surveillance and coordination of all treatments and check-ups.
More Articles on Hospital Oncology:
Commonwealth Cancer Centers of Kentucky Joins UK Markey Cancer Center NetworkPacific Cancer Institute of Maui to Begin $7M Expansion
Mayo Clinic Names Coborn Cancer Center First Member of New Cancer Care Network